ECCS 50

Drug Profile

ECCS 50

Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Cytori Therapeutics; Adipose-derived stem cells - Cytori Therapeutics; ADRCs - Cytori Therapeutics; Cytori Cell Therapy; ECCI 50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytori Therapeutics
  • Developer Assistance Publique - Hopitaux de Marseille
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma

Most Recent Events

  • 24 Jul 2017 Top-line efficacy and adverse events data from the phase III STAR trial in Scleroderma released by Cytori Therapeutics
  • 05 Jul 2017 Cytori has patent protection for the use of adipose-derived regenerative cells for the treatment of scleroderma, including treatment of Raynaud’s Phenomenon or suppression of pain from Raynaud’s Phenomenon in European Union
  • 14 Jun 2017 Cytori Therapeutics initiates Managed Access Programme for Scleroderma in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top